Allegro Ophthalmics LLC

34 articles about Allegro Ophthalmics LLC

• Allegro Ophthalmics LLC Announces Last Patient Enrolled In PACIFIC Phase IIb Clinical Trial Of Luminate For Non-Proliferative Diabetic Retinopathy

  10/3/2016

• Ron Kurtz, MD, And Mark Livingston Join Allegro Ophthalmics LLC’ Board Of Directors

  8/1/2016

• Allegro Ophthalmics LLC Announces Two Executive Promotions

  3/15/2016

• Allegro Ophthalmics LLC Announces Last Patient Enrolled In DEL MAR Phase IIb Clinical Trial Of Luminate For The Treatment Of Diabetic Macular Edema

  1/5/2016

• Allegro Ophthalmics LLC Names Scott Cooper As Chief Financial Officer And Vice President Of Business Development And Mohamed Genead, MD, As Executive Medical Director

  10/21/2015

• Allegro Ophthalmics LLC Announces Positive Topline Results From Phase II Trial Evaluating Luminate® In Patients With Vitreomacular Traction Or Vitreomacular Adhesion

  7/13/2015

• Allegro Ophthalmics LLC Announces Issuance Of U.S. Patent For First-In-Class Integrin Peptide Therapy Candidate Luminate

  5/18/2015

• Allegro Ophthalmics LLC Begins Phase II Clinical Study Of Luminate® For Non-Proliferative Diabetic Retinopathy

  5/4/2015

• Allegro Ophthalmics LLC Awarded $2 Million Grant From Helmsley Charitable Trust

  2/3/2015

• Allegro Ophthalmics LLC And Hanmi Pharmaceutical, Co., Ltd Announce Strategic Investment And Collaboration To Develop And Market Luminate® In The Republic Of Korea And China

  1/13/2015

• Allegro Ophthalmics LLC Begins Phase 2 Clinical Trial Of Luminate® (ALG-1001) For The Treatment Of Diabetic Macular Edema

  10/16/2014

• Allegro Ophthalmics LLC Announces Commencement of First Human Subject Study With ALG-1001 to Treat Vitreomacular Traction

  11/4/2013

• Allegro Ophthalmics LLC and the Helmsley Charitable Trust to Present at Partnering for Cures

  10/31/2013

• Allegro Ophthalmics LLC Receives FDA IND Approval for Phase 2 Clinical Studies With First in Class Integrin Peptide Therapy ALG-1001

  10/9/2013